Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Multi-Billion Dollar Potential Market for COVD-19 Vaccine, Per Market Research Firm

Healthcare publisher, Kalorama Information, shares details of its recent report on vaccine development and production trends.


News provided by

Kalorama Information

May 20, 2020, 15:00 ET

Share this article

Share toX

Share this article

Share toX


ARLINGTON, Va., May 20, 2020 /PRNewswire-PRWeb/ -- As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19 vaccine candidates, five of which have already entered clinical trials. In its recent report on vaccine development, Kalorama Information, part of Science and Medicine Group, has tracked companies that are developing vaccines for COVID-19. The firm says that a vaccine for COVID-19 would create a market worth billions in revenue, perhaps even as much as ten billion, but that companies would also incur large R&D spends and production challenges which have always keep profit margins in the industry on the low side. Kalorama has covered vaccines in market research studies for two decades.

Vaccination protects not only individuals, but also entire communities from diseases spread by person-to-person transmission. When immunization programs achieve high levels of "community" immunity, the likelihood that an infected person will transmit the disease to a susceptible individual is greatly reduced. Vaccination can prevent about 50% of deaths from pneumococcal disease and 80% of deaths from influenza-related complications in the elderly. Pharmacoeconomic studies have demonstrated the value of influenza and pneumococcal vaccines; however, despite various vaccination campaigns and promotional efforts, immunization rates for these diseases continue to be low in the elderly population.

Only 45% of US adults tend to get the flu shot, depending on the severity of the flu season. Presumably, many more will rush to get the COVID-19 vaccine, and we expect more attention on flu as well because of the attention on respiratory disease transmission.

Post this

In the U.S., for example, the Centers for Disease Control (CDC) has found that Influenza is responsible for 20,000 to 40,000 deaths annually, and up to 50,000 deaths and an estimated 200,000 excess hospitalizations at a cost of $750 million to $1 billion during epidemic years. Also mortality from all pneumococcal disease, also vaccine-mitigatable, results in about 40,000 deaths annually, with morbidity estimated at 500,000 cases of pneumonia.

"Only 45% of US adults tend to get the flu shot, depending on the severity of the flu season," said Bruce Carlson, Publisher of Kalorama Information. "Presumably, many more will rush to get the COVID-19 vaccine, and we expect more attention on flu as well because of the attention on respiratory disease transmission."

Influenza vaccines generated $5.1 billion in revenues. Sales fluctuate from year to year with a variety of factors including new influenza strains and outbreaks, government contracts and stockpiling, new production formats and rising demand in developing countries affecting demand.

Roughly estimated market demand based on comparison to flu vaccine alone, Kalorama believes the market for COVID-19 could be 8-10 billion dollars in its first full year of implementation. It would represent a quarter of the vaccine market in that year.

"But there will likely be many factors that would move that number up or down," said Carlson. "Price, supply, government intervention, stockpiling effects all could temporarily create a very large or smaller than expected market."

Carlson also noted that such a vaccine could start out at a high market figure and then in the future settle down to a more stable number as it becomes standard and as competition is introduced, which has been the case with cervical cancer, travel and flu vaccines.

Many vaccine trials are underway, some for diseases such as breast cancer, HIV, and malaria. But because of the nature of the severity of the COVID-19 pandemic, vaccine manufacturers are prioritizing the development of COVID-19 vaccines. As of April 20, 2020, several candidates for a COVID-19 vaccine are showing promise:

  • CanSino Biologics is developing a vaccine for the prevention of COVID-19, Ad5-nCoV, a recombinant vaccine incorporating the adenovirus type 5 vector. On March 8, 2020, CanSino received approval from the Chinese authorities to begin human trials. This is the first coronavirus vaccine to advance to phase II trials.
  • Moderna offers its mRNA-1273, a novel lipid nanoparticle-encapsulated mRNA vaccine encoding for a perfusion-stabilized form of the SARS-CoV-2 spike protein. On March 16, 2020, the company began its phase I open-label, dose-ranging trial, occurring at Kaiser Permanente Washington Health Research Institute in Seattle. The company says it has applied for Phase II.
  • Inovio Pharmaceuticals announced that CEPI provided a grant to develop a vaccine against COVID-19 called INO-4800. The company is collaborating with Beijing Advaccine Biotechnology to advance the product. Preclinical testing has begun, with human clinical trials to commence in April 2020 in the U.S., China, and South Korea. It is anticipated that with positive results, some 1 million doses of the INO-4800 DNA vaccine can be produced by the end of 2020. On April 6, 2020, the company received approval to begin phase I trials. The Bill and Melinda Gates Foundation, along with other nonprofits, is supporting Inovio's COVID-19 vaccine project.
  • Shenzhen Geno-Immune Medical Institute offers the LV-SMENP-DC vaccine. The LV-SMENP-DC vaccine is made by modifying dendritic cells (DC) with lentivirus vectors expressing COVID-19 minigene SMENP and immune-modulatory genes. CTLs will be activated by LV-DC presenting COVID-19 specific antigens. The project is in phase I.
  • Shenzhen Geno-Immune Medical Institute has a second product -- the COVID-19/aAPC vaccine. The COVID-19/aAPC vaccine is prepared by applying lentivirus modifications, including immune-modulatory genes and the viral minigenes, to the artificial antigen-presenting cells (aAPCs). It is also in phase I.

Many vaccine trials are underway, some for diseases such as breast cancer, HIV, and malaria. But because of the nature of the severity of the COVID-19 pandemic, vaccine manufacturers are prioritizing the development of COVID-19 vaccines. As of April 20, 2020, several candidates for a COVID-19 vaccine are showing promise including CanSino, Moderna, Inovio and others. Kalorama Information's vaccine production report is available at: https://kaloramainformation.com/product/vaccine-development-and-production-trends-covid-19-and-other-vaccines-pipeline/.

About Kalorama Information
For more than 30 years, Kalorama Information has been a leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), biotechnology, healthcare, medical devices, and pharmaceuticals.

SOURCE Kalorama Information

Related Links

https://kaloramainformation.com/

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.